QR Pharma Reports Results from SBIR Grant by NIA/National Institutes of Health (NIH) to Study Posiphen(R) and Metabolites in Various Models

Published: Oct 13, 2011

BERWYN, Pa.--(BUSINESS WIRE)--QR Pharma, Inc. (QR), a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer’s disease (AD), along with the Medical University of South Carolina (MUSC) report on the results obtained from the Small Business Innovation Research (SBIR) phase I grant study on Posiphen®. The grant complements QR’s study in mildly cognitive impaired (MCI) patients and shows that in all systems tested: tissue culture cells, AD transgenic mice and MCI patients Posiphen reproducibly has the same effects.

Back to news